1. Scrip
  2. >>Therapy Areas

DBV Soars As Path For Peanut Allergy Patch Approval Clears

Positive FDA Feedback After Earlier Rejection

 
• By Kevin Grogan

The French biotech's chances of competing with Aimmune's Palforzia in the peanut allergy market have been boosted after US regulators decided that a fresh Phase III trial for the Viaskin Peanut patch would not be required for resubmission.

Peanut_Butter
DBV hopes to help children with peanut allergy • Source: Archive

DBV Technologies' peanut allergy patch has been on shaky ground since a rejection from US regulators in August last year but the path to potential approval has become clearer after the French firm's positive meeting with the Food and Drug Administration.

The future for DBV looked bleak last summer when the FDA issued a complete response letter to the biologics license...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By Kevin Grogan

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

 
• By Andrew McConaghie

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.

J&J Seeks Schizophrenia Relapse Indication For Caplyta

 
• By Jessica Merrill

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.